- Exchange: NASDAQ CM
- Sector: Consumer, Non-cyclical
- Industry: Pharmaceuticals
- Sub-Industry: Medical-Drugs
Ventrus Biosciences Inc
+ Add to WatchlistVTUS:US
2.6600 USD 0.0200 0.76%As of 20:10:00 ET on 05/17/2013.
Snapshot for Ventrus Biosciences Inc (VTUS)
| Open: | 2.6600 | Day's Range: | 2.6400 - 2.6900 | Volume: | 48,915 |
|---|---|---|---|---|---|
| Previous Close: | 2.6400 | 52wk Range: | 1.9900 - 12.8800 | 1-Yr Rtn: | -74.67% |
Key Statistics for VTUS
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(12/2013) | - |
| Relative P/E vs. SPX | - |
| Earnings Per Share (USD) (ttm) | -1.9500 |
| Est. EPS (USD) (12/2013) | -0.8670 |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 52.15 |
| Shares Outstanding (M) | 19.60 |
| 30 Day Average Volume | 85,909 |
| Price/Book (mrq) | 1.9318 |
| Price/Sale (ttm) | - |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 05/23/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for VTUS
No data available
Company Profile & Key Executives for VTUS
Ventrus Biosciences Inc. is a development stage pharmaceutical company. The Company is focused on late-stage prescription drugs for gastrointestinal disorders, specifically hemorrhoids, anal fissures and fecal incontinence. Ventrus's lead products are topical treatments for hemorroids, which targets a specific serotonin receptor.
| Russell H EllisonChairman/President/CEO | David J BarrettChief Financial Officer |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
VTUS News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page